Glenmark Pharmaceuticals U.S. > News

News

Press Releases

Get access to Glenmark information and resources for stories in development.
Find recent and archived press releases.

Glenmark receives ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg

May 26, 2017

Glenmark Pharmaceuticals receives ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg

May 26, 2017

Glenmark Pharmaceuticals to Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio

May 15, 2017

Glenmark’s consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 – 17

May 11, 2017

Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR®

April 25, 2017

News

Search Result :-

Is an investigational new drug that has not been approved for commercial distribution in the United States.

May 26, 2017
Glenmark receives ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg

May 26, 2017
Glenmark Pharmaceuticals receives ANDA approval for Olmesartan Medoxomil Tablets, 5 mg, 20 mg and 40 mg

May 15, 2017
Glenmark Pharmaceuticals to Initiate Clinical Study for GBR 1342, Second Investigational New Drug from Immuno-Oncology Portfolio

May 11, 2017
Glenmark’s consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016 – 17

April 25, 2017
Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR®

US Media Contact

For media inquiries only, please contact Corporate Communications.
uscomms@glenmarkpharma.com

Investor Relations

For more information on Glenmark Pharmaceuticals Ltd., including Annual Reports, Analyst Presentations and Financial Results, please visit our Investor Relations.

POTASSIUM CHLORIDE EXTENDED RELEASE CAPSULES 750mg RECALL REIMBURSEMENT POLICY

Over-the-counter (OTC)

ACCESSIBLE PRODUCTS

Who We Are

Injectables

OUR GROWING LINE